Amryt exits 2020 with strong performances across all metrics: good momentum in the underlying business; continued EBITDA growth; and strong cash generation. Following the positive phase III results for Filsuvez in September, US and EU drug approval could occur before year end, with commercial launch shortly thereafter. We note the balance sheet is in a healthy state to execute on further business development opportunities that can supplement core organic growth. We expect to leave our forecasts broadly unchanged at this point. We reiterate our price target of £4.80.
Davy research
Davy ResearchBank of Ireland - Positive catalyst: material scale benefits from KBC Ireland exit
Davy ResearchGrafton Group - Announces strategic review of traditional merchanting operations in Great Britain
Davy ResearchHeidelbergCement AG - Q1 out-turn comfortably ahead of estimates
Davy ResearchMarket comment - Irish residential property price inflation accelerates to 3%
Davy ResearchWizz Air Holdings - Tough Q4 means weaker-than-expected full-year out-turn
Davy ResearchTravis Perkins plc - Big increase in underlying revenues in Q1
Davy ResearchMarket comment - Stability Programme Update puts off difficult questions